9th March 2010 - New research
PARDOPRUNOX - A PARTIAL DOPAMINE AGONIST FOR PARKINSON'S DISEASE
Movement Disorders [2010] Mar 2. [Epub ahead of print] (Bronzova J, Sampaio C,
Hauser RA, Lang AE, Rascol O, Theeuwes A, van de Witte SV, van Scharrenburg G)
Complete abstract
Pardoprunox is a new partial dopamine agonist from Solvay being assessed for
its potential future use in the treatment of Parkinson's Disease. It unusually
combines two effects as if it were two distinct but combined drugs :
partially stimulating dopamine, whose deficiency causes Parkinson's Disease,
and fully stimulating serotonin, which is another chemical naturally produced
in the brain. It is thought that Pardoprunox could avoid some of the severe
side effects that full dopamine agonists cause by lessening the effect of
dopamine when dopamine activity is high. This study examined the efficacy and
safety of Pardoprunox (SLV308), in the treatment of patients with early
Parkinson's Disease. Parkinson's Disease symptoms did reduce when taking
Pardoprunox. Activities of daily living in people with Parkinson's Disease
also improved. Nausea was reported by 47% of patients. Dizziness, somnolence,
headache, asthenia were reported far less commonly. The effects of Pardoprunox
are to be assessed further.
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
